3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Stomach Neoplasms
7
Rectal Neoplasms
5
Nasopharyngeal Carcinoma
5
Colorectal Neoplasms
5
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Pancreatic Neoplasms
3
Melanoma
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Advanced Solid Tumor
2
Triple Negative Breast Neoplasms
1
Squamous Cell Non-small Cell Lung Cancer
1
Solid Tumor, Adult
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms by Site
1
Interventions
Drug Therapy
2
trastuzumab deruxtecan
1
spartalizumab
1
sacituzumab govitecan
1
Radiotherapy
1
Nivolumab
1
Interleukin-2
1
Fecal Microbiota Transplantation
1
Docetaxel
1
Cyclophosphamide
1
Cisplatin
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Drug-Related Side Effects and Adverse Reactions
×
spartalizumab
×
Clear all
NCT06302062
2024-12-03
TAL-T
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
Recruiting
23 enrolled